Epizyme, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Bazemore
- Full Time Employees
- 250
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 Technology Sq Ste 4 Cambridge MA United States of America 02139
- IPO Date
- May 31, 2013
- CIK
- 0001571498
- Website
- epizyme.com
- Similar Companies
- Business
- Epizyme, Inc. (EPZM) develops and commercializes small molecule inhibitors targeting epigenetic enzymes for cancer therapy. The company offers tazemetostat, a selective inhibitor of the EZH2 enzyme approved for treating metastatic or locally advanced epithelioid sarcoma and relapsed or refractory follicular lymphoma; it also advances a pipeline of early-stage candidates including pinometostat (DOT1L inhibitor), cemdemistat (LSD1 inhibitor), and preclinical EZH2 degraders. Epizyme operates in the biotechnology sector, focusing on oncology; its target markets include patients with genetically defined solid tumors and hematologic malignancies; the company, founded in 2007 and headquartered in Cambridge, Massachusetts, conducts research and clinical development primarily in the United States and Europe. In recent major developments, Ipsen completed its acquisition of Epizyme in May 2022, integrating tazemetostat into its oncology portfolio; post-acquisition, Epizyme's operations have been consolidated under Ipsen as a subsidiary, with no independent public trading since delisting from NASDAQ.
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Epizyme, Inc. Merger
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM
SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.
Why Epizyme Stock Is Soaring Today
Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Ipsen to acquire U.S.-based Epizyme for $247 million.
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?